Blastic plasmacytoid dendritic cell neoplasm (BPDCN) arising in the setting of polycythemia vera (PV): An illustration of the emerging role of flow cytometry analysis in monitoring progression of myeloproliferative neoplasms

This report highlights the value of flow cytometry analysis, particularly in the setting of myeloproliferative neoplasms showing features of progression, as neoplastic plasmacytoid dendritic cell (PDC) proliferations may be present, representing either a clonal expansion of mature PDCs related to the underlying myeloproliferative neoplasm or transformation to blastic plasmacytoid dendritic cell neoplasm (BPDCN). BPDCN should always be considered in patients with myeloid neoplasms in progression and/or who develop new cutaneous findings, as it may prompt change of management.

[1]  L. Medeiros,et al.  Blastic plasmacytoid dendritic cell neoplasm with history of myeloma and concomitant acute undifferentiated leukemia: Illustration of morphologic and immunophenotypic challenges of an emerging phenomenon , 2021, Leukemia & lymphoma.

[2]  N. Pemmaraju.  Targeting the p-D-C: easy as C-D-1-2-3? , 2021, Blood.

[3]  F. Jardin,et al.  Plasmacytoid dendritic cells proliferation associated with acute myeloid leukemia: phenotype profile and mutation landscape , 2020, Haematologica.

[4]  B. Thakral,et al.  CD123+CD4+CD56+ neoplasm: blastic plasmacytoid dendritic cell neoplasm or acute myeloid leukemia? , 2020, Blood.

[5]  M. Arcila,et al.  Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1 mutated acute myeloid leukemia. , 2020, Blood.

[6]  L. Medeiros,et al.  Immunophenotypic characterization of reactive and neoplastic plasmacytoid dendritic cells permits establishment of a ten-color flow cytometric panel for initial workup and residual disease evaluation of blastic plasmacytoid dendritic cell neoplasm , 2020, Haematologica.

[7]  M. Gobbi,et al.  Prognostic relevance of a blastic plasmacytoid dendritic cell neoplasm-like immunophenotype in cytogenetically normal acute myeloid leukemia patients , 2020, Leukemia & lymphoma.

[8]  H. Meyerson,et al.  Flow Cytometry Identifies a Spectrum of Maturation in Myeloid Neoplasms Having Plasmacytoid Dendritic Cell Differentiation , 2020, Cytometry. Part B, Clinical cytometry.

[9]  Yan-rong Liu,et al.  Myeloid Neoplasms with Elevated Plasmacytoid Dendritic Cell Differentiation Reflect the Maturation Process of Dendritic Cells , 2019, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[10]  Hannah C. Beird,et al.  Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Commonly Presents in the Setting of Prior or Concomitant Hematologic Malignancies (PCHM): Patient Characteristics and Outcomes in the Rapidly Evolving Modern Targeted Therapy Era , 2019, Blood.

[11]  E. Solary,et al.  Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia , 2019, Leukemia.

[12]  M. Gobbi,et al.  A blastic plasmacytoid dendritic cell neoplasm‐like phenotype identifies a subgroup of npm1‐mutated acute myeloid leukemia patients with worse prognosis , 2018, American journal of hematology.

[13]  S. Swerdlow.  WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , 2017 .

[14]  W. Vermi,et al.  Neoplasms derived from plasmacytoid dendritic cells , 2016, Modern Pathology.

[15]  T. Petrella,et al.  Specific Skin Lesions in Chronic Myelomonocytic Leukemia: A Spectrum of Myelomonocytic and Dendritic Cell Proliferations. A Study of 42 Cases , 2012, The American journal of surgical pathology.